Gene therapy for ischemic heart disease

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 5, 2011, Pages 742-750

  Lavu, Madhav ^a   Gundewar, Susheel ^b   Lefer, David J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular therapy; Gene transfer; Ischemic heart disease

Indexed keywords

ADENOVIRUS VECTOR; CD151 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; HEAT SHOCK PROTEIN 72; HEME OXYGENASE 1; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SCATTER FACTOR; SOLUBLE TUMOR NECROSIS FACTOR ALPHA; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; THIOREDOXIN 1; TROPONIN I; TROPONIN I TYPE 3 INTERACTING KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR B186; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR RESPONSE; CELL SURVIVAL; CELL TRANSPLANTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOBLAST; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

CLINICAL TRIALS AS TOPIC; FIBROBLAST GROWTH FACTORS; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; MYOCARDIAL ISCHEMIA; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 79953686216     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.06.007     Document Type: Review

References (158)

1. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113(6):e85-e151.
2. Suzuki K., Murtuza B., Smolenski R.T., Sammut I.A., Suzuki N., Kaneda Y., et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001, 104(12 Suppl 1):I207-I212.
3. Askari A., Unzek S., Goldman C.K., Ellis S.G., Thomas J.D., DiCorleto P.E., et al. Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. J Am Coll Cardiol 2004, 43(10):1908-1914.
4. Ye L., Haider H., Jiang S., Tan R.S., Toh W.C., Ge R., et al. Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies. Eur J Heart Fail 2007, 9(5):458-465.
5. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999, 237:1-30.
6. Zhao T., Zhao W., Chen Y., Ahokas R.A., Sun Y. Vascular Endothelial Growth Factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res 2010.
7. Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005, 65(3):550-563.
8. Bellomo D., Headrick J.P., Silins G.U., Paterson C.A., Thomas P.S., Gartside M., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000, 86(2):E29-E35.
9. Olofsson B., Korpelainen E., Pepper M.S., Mandriota S.J., Aase K., Kumar V., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998, 95(20):11709-11714.
10. Breier G., Clauss M., Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995, 204(3):228-239.
11. Rissanen T.T., Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007, 15(7):1233-1247.
12. Hao X., Mansson-Broberg A., Grinnemo K.H., Siddiqui A.J., Dellgren G., Brodin L.A., et al. Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc Res 2007, 73(3):481-487.
13. Ruixing Y., Jiaquan L., Jie C., Dezhai Y. Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis. Growth Factors 2006, 24(3):209-217.
14. Bull D.A., Bailey S.H., Rentz J.J., Zebrack J.S., Lee M., Litwin S.E., et al. Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. J Control Release 2003, 93(2):175-181.
15. Tio R.A., Tkebuchava T., Scheuermann T.H., Lebherz C., Magner M., Kearny M., et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999, 10(18):2953-2960.
16. Jacquier A., Higgins C.B., Martin A.J., Do L., Saloner D., Saeed M. Injection of adeno-associated viral vector encoding vascular endothelial growth factor gene in infarcted swine myocardium: MR measurements of left ventricular function and strain. Radiology 2007, 245(1):196-205.
17. Choi J.S., Kim K.B., Han W., Kim D.S., Park J.S., Lee J.J., et al. Efficacy of therapeutic angiogenesis by intramyocardial injection of pCK-VEGF165 in pigs. Ann Thorac Surg 2006, 82(2):679-686.
18. Zhang D., Gai L., Fan R., Dong W., Wen Y. Efficacy and safety of therapeutic angiogenesis from direct myocardial administration of an adenoviral vector expressing vascular endothelial growth factor 165. Chin Med J (Engl) 2002, 115(5):643-648.
19. Ferrarini M., Arsic N., Recchia F.A., Zentilin L., Zacchigna S., Xu X., et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006, 98(7):954-961.
20. Lee L.Y., Patel S.R., Hackett N.R., Mack C.A., Polce D.R., El-Sawy T., et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000, 69(1):14-23. discussion -4.
21. Mack C.A., Patel S.R., Schwarz E.A., Zanzonico P., Hahn R.T., Ilercil A., et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998, 115(1):168-176. discussion 76-7.
22. Heilmann C.A., Attmann T., von Samson P., Gobel H., Marme D., Beyersdorf F., et al. Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia-do the effects really add up?. Eur J Cardiothorac Surg 2003, 23(1):74-80.
23. Sayeed-Shah U., Mann M.J., Martin J., Grachev S., Reimold S., Laurence R., et al. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. J Thorac Cardiovasc Surg 1998, 116(5):763-769.
24. Hagberg C.E., Falkevall A., Wang X., Larsson E., Huusko J., Nilsson I., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010.
25. Li X., Tjwa M., Van Hove I., Enholm B., Neven E., Paavonen K., et al. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol 2008, 28(9):1614-1620.
26. Lahteenvuo J.E., Lahteenvuo M.T., Kivela A., Rosenlew C., Falkevall A., Klar J., et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009, 119(6):845-856.
27. Patila T., Ikonen T., Rutanen J., Ahonen A., Lommi J., Lappalainen K., et al. Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia. J Heart Lung Transplant 2006, 25(2):206-213.
28. Rutanen J., Rissanen T.T., Markkanen J.E., Gruchala M., Silvennoinen P., Kivela A., et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004, 109(8):1029-1035.
29. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001, 7(4):425-429.
30. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102(8):898-901.
31. Schwarz E.R., Speakman M.T., Patterson M., Hale S.S., Isner J.M., Kedes L.H., et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 2000, 35(5):1323-1330.
32. Lee M., Rentz J., Bikram M., Han S., Bull D.A., Kim S.W. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther 2003, 10(18):1535-1542.
33. Su H., Arakawa-Hoyt J., Kan Y.W. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci U S A 2002, 99(14):9480-9485.
34. Yockman J.W., Choi D., Whitten M.G., Chang C.W., Kastenmeier A., Erickson H., et al. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther 2009, 16(1):127-135.
35. Dong H., Wang Q., Zhang Y., Jiang B., Xu X., Zhang Z. Angiogenesis induced by hVEGF165 gene controlled by hypoxic response elements in rabbit ischemia myocardium. Exp Biol Med (Maywood) 2009, 234(12):1417-1424.
36. Morishita R., Aoki M., Yo Y., Ogihara T. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocr J 2002, 49(3):273-284.
37. Aoki M., Morishita R., Taniyama Y., Kida I., Moriguchi A., Matsumoto K., et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000, 7(5):417-427.
38. Funatsu T., Sawa Y., Ohtake S., Takahashi T., Matsumiya G., Matsuura N., et al. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J Thorac Cardiovasc Surg 2002, 124(6):1099-1105.
39. Wang W., Yang Z.J., Ma D.C., Wang L.S., Xu S.L., Zhang Y.R., et al. Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol Sin 2006, 27(5):555-560.
40. Li Y., Takemura G., Kosai K., Yuge K., Nagano S., Esaki M., et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003, 107(19):2499-2506.
41. Jin H., Wyss J.M., Yang R., Schwall R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004, 10(20):2525-2533.
42. Jayasankar V., Woo Y.J., Bish L.T., Pirolli T.J., Chatterjee S., Berry M.F., et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003, 108(Suppl 1):II230-II236.
43. Yang Z.J., Chen B., Sheng Z., Zhang D.G., Jia E.Z., Wang W., et al. Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium- and high-dose groups. Mol Biol Rep 2010, 37(4):2075-2081.
44. Yang Z., Wang W., Ma D., Zhang Y., Wang L., Xu S., et al. Recruitment of stem cells by hepatocyte growth factor via intracoronary gene transfection in the postinfarction heart failure. Sci China C Life Sci 2007, 50(6):748-752.
45. Ahmet I., Sawa Y., Iwata K., Matsuda H. Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: a novel gene therapy for cardiomyopathy. J Thorac Cardiovasc Surg 2002, 124(5):957-963.
46. Taniyama Y., Morishita R., Aoki M., Hiraoka K., Yamasaki K., Hashiya N., et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002, 40(1):47-53.
47. Cho K.R., Choi J.S., Hahn W., Kim D.S., Park J.S., Lee D.S., et al. Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg 2008, 34(4):857-863.
48. Ahmet I., Sawa Y., Yamaguchi T., Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003, 75(4):1283-1287.
49. Kondo I., Ohmori K., Oshita A., Takeuchi H., Fuke S., Shinomiya K., et al. Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction. J Am Coll Cardiol 2004, 44(3):644-653.
50. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):REVIEWS3005.
51. Khurana R., Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 2003, 13(3):116-122.
52. Horvath K.A., Doukas J., Lu C.Y., Belkind N., Greene R., Pierce G.F., et al. Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging. Ann Thorac Surg 2002, 74(2):481-486. discussion 7.
53. Heilmann C., von Samson P., Schlegel K., Attmann T., von Specht B.U., Beyersdorf F., et al. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur J Cardiothorac Surg 2002, 22(6):957-964.
54. Post M.J., Sato K., Murakami M., Bao J., Tirziu D., Pearlman J.D., et al. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. Am J Physiol Regul Integr Comp Physiol 2006, 290(3):R494-R500.
55. Gao M.H., Lai N.C., McKirnan M.D., Roth D.A., Rubanyi G.M., Dalton N., et al. Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor 4: report of preclinical data. Hum Gene Ther 2004, 15(6):574-587.
56. Giordano F.J., Ping P., McKirnan M.D., Nozaki S., DeMaria A.N., Dillmann W.H., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996, 2(5):534-539.
57. Suzuki G., Lee T.C., Fallavollita J.A., Canty J.M. Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle. Circ Res 2005, 96(7):767-775.
58. Atkins B.Z., Hueman M.T., Meuchel J., Hutcheson K.A., Glower D.D., Taylor D.A. Cellular cardiomyoplasty improves diastolic properties of injured heart. J Surg Res 1999, 85(2):234-242.
59. Hattan N., Warltier D., Gu W., Kolz C., Chilian W.M., Weihrauch D. Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth. Am J Physiol Heart Circ Physiol 2004, 287(2):H488-H493.
60. Ninomiya M., Koyama H., Miyata T., Hamada H., Miyatake S., Shigematsu H., et al. Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model. Gene Ther 2003, 10(14):1152-1160.
61. Haider H., Ye L., Jiang S., Ge R., Law P.K., Chua T., et al. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 2004, 82(8):539-549.
62. Ye L., Haider H., Tan R., Toh W., Law P.K., Tan W., et al. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 2007, 116(11 Suppl):I113-I120.
63. Yau T.M., Kim C., Ng D., Li G., Zhang Y., Weisel R.D., et al. Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg 2005, 80(5):1779-1786.
64. Elmadbouh I., Haider H., Jiang S., Idris N.M., Lu G., Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007, 42(4):792-803.
65. Azarnoush K., Maurel A., Sebbah L., Carrion C., Bissery A., Mandet C., et al. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. J Thorac Cardiovasc Surg 2005, 130(1):173-179.
66. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004, 95(1):9-20.
67. Matsumoto R., Omura T., Yoshiyama M., Hayashi T., Inamoto S., Koh K.R., et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005, 25(6):1168-1173.
68. Chen S.Y., Wang F., Yan X.Y., Zhou Q., Ling Q., Ling J.X., et al. Autologous transplantation of EPCs encoding FGF1 gene promotes neovascularization in a porcine model of chronic myocardial ischemia. Int J Cardiol 2009, 135(2):223-232.
69. Miyagawa S., Sawa Y., Taketani S., Kawaguchi N., Nakamura T., Matsuura N., et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002, 105(21):2556-2561.
70. Lim S.Y., Kim Y.S., Ahn Y., Jeong M.H., Hong M.H., Joo S.Y., et al. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res 2006, 70(3):530-542.
71. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003, 9(9):1195-1201.
72. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11(4):367-368.
73. Liu X.H., Bai C.G., Xu Z.Y., Huang S.D., Yuan Y., Gong D.J., et al. Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvasc Res 2008, 76(1):23-30.
74. Wang X., Zhao T., Huang W., Wang T., Qian J., Xu M., et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells 2009, 27(12):3021-3031.
75. Li W., Ma N., Ong L.L., Nesselmann C., Klopsch C., Ladilov Y., et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007, 25(8):2118-2127.
76. Tang Y.L., Tang Y., Zhang Y.C., Qian K., Shen L., Phillips M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005, 46(7):1339-1350.
77. Ahmed R.P., Haider K.H., Shujia J., Afzal M.R., Ashraf M. Sonic Hedgehog gene delivery to the rodent heart promotes angiogenesis via iNOS/netrin-1/PKC pathway. PLoS ONE 2010, 5(1):e8576.
78. Jiang S., Haider H., Idris N.M., Salim A., Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006, 99(7):776-784.
79. Yau T.M., Kim C., Li G., Zhang Y., Weisel R.D., Li R.K. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 2005, 112(9 Suppl):I123-I128.
80. Yau T.M., Kim C., Li G., Zhang Y., Fazel S., Spiegelstein D., et al. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg 2007, 83(3):1110-1119.
81. Das H., George J.C., Joseph M., Das M., Abdulhameed N., Blitz A., et al. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS ONE 2009, 4(10):e7325.
82. Chen H.K., Hung H.F., Shyu K.G., Wang B.W., Sheu J.R., Liang Y.J., et al. Combined cord blood stem cells and gene therapy enhances angiogenesis and improves cardiac performance in mouse after acute myocardial infarction. Eur J Clin Invest 2005, 35(11):677-686.
83. Abrescia P., Golino P. Free radicals and antioxidants in cardiovascular diseases. Expert Rev Cardiovasc Ther 2005, 3(1):159-171.
84. Cantor E.J., Mancini E.V., Seth R., Yao X.H., Netticadan T. Oxidative stress and heart disease: cardiac dysfunction, nutrition, and gene therapy. Curr Hypertens Rep 2003, 5(3):215-220.
85. Dhalla N.S., Temsah R.M., Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000, 18(6):655-673.
86. Higashi Y., Nishioka K., Umemura T., Chayama K., Yoshizumi M. Oxidative stress, endothelial function and angiogenesis induced by cell therapy and gene therapy. Curr Pharm Biotechnol 2006, 7(2):109-116.
87. Levonen A.L., Vahakangas E., Koponen J.K., Yla-Herttuala S. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation 2008, 117(16):2142-2150.
88. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006, 71(2):310-321.
89. Wu J., Hecker J.G., Chiamvimonvat N. Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev 2009, 61(4):351-363.
90. Li Q., Bolli R., Qiu Y., Tang X.L., Murphree S.S., French B.A. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 1998, 98(14):1438-1448.
91. Li Q., Bolli R., Qiu Y., Tang X.L., Guo Y., French B.A. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation 2001, 103(14):1893-1898.
92. Agrawal R.S., Muangman S., Layne M.D., Melo L., Perrella M.A., Lee R.T., et al. Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. Gene Ther 2004, 11(12):962-969.
93. Yang J., Marden J.J., Fan C., Sanlioglu S., Weiss R.M., Ritchie T.C., et al. Genetic redox preconditioning differentially modulates AP-1 and NF kappa B responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis. Mol Ther 2003, 7(3):341-353.
94. Abunasra H.J., Smolenski R.T., Morrison K., Yap J., Sheppard M.N., O'Brien T., et al. Efficacy of adenoviral gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion injury. Eur J Cardiothorac Surg 2001, 20(1):153-158.
95. Liu X., Simpson J.A., Brunt K.R., Ward C.A., Hall S.R., Kinobe R.T., et al. Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol 2007, 293(1):H48-H59.
96. Melo L.G., Agrawal R., Zhang L., Rezvani M., Mangi A.A., Ehsan A., et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002, 105(5):602-607.
97. Liu X., Pachori A.S., Ward C.A., Davis J.P., Gnecchi M., Kong D., et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J 2006, 20(2):207-216.
98. Dulak J., Jozkowicz A., Foresti R., Kasza A., Frick M., Huk I., et al. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid Redox Signal 2002, 4(2):229-240.
99. Tang Y.L., Qian K., Zhang Y.C., Shen L., Phillips M.I. A vigilant, hypoxia-regulated heme oxygenase-1 gene vector in the heart limits cardiac injury after ischemia-reperfusion in vivo. J Cardiovasc Pharmacol Ther 2005, 10(4):251-263.
100. Tao L., Gao E., Bryan N.S., Qu Y., Liu H.R., Hu A., et al. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A 2004, 101(31):11471-11476.
101. Tao L., Gao E., Hu A., Coletti C., Wang Y., Christopher T.A., et al. Thioredoxin reduces post-ischemic myocardial apoptosis by reducing oxidative/nitrative stress. Br J Pharmacol 2006, 149(3):311-318.
102. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Koneru S., Zhan L., Maulik G., et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 16 2010, 121(10):1244-1255.
103. Jones S.P., Greer J.J., Kakkar A.K., Ware P.D., Turnage R.H., Hicks M., et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004, 286(1):H276-H282.
104. Chen L.L., Yin H., Huang J. Inhibition of TGF-beta1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc Pathol 2007, 16(4):221-230.
105. Chen L.L., Zhu T.B., Yin H., Huang J., Wang L.S., Cao K.J., et al. Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation. Mol Biol Rep 2009.
106. Smith R.S., Agata J., Xia C.F., Chao L., Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 2005, 76(21):2457-2471.
107. Kupatt C., Hinkel R., Vachenauer R., Horstkotte J., Raake P., Sandner T., et al. VEGF165 transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation. FASEB J 2003, 17(6):705-707.
108. Li Q., Guo Y., Tan W., Stein A.B., Dawn B., Wu W.J., et al. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 2006, 290(2):H584-H589.
109. Li Q., Guo Y., Xuan Y.T., Lowenstein C.J., Stevenson S.C., Prabhu S.D., et al. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 2003, 92(7):741-748.
110. Li Q., Guo Y., Ou Q., Cui C., Wu W.J., Tan W., et al. Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. Circulation 2009, 120(13):1222-1230.
111. Okubo S., Wildner O., Shah M.R., Chelliah J.C., Hess M.L., Kukreja R.C. Gene transfer of heat-shock protein 70 reduces infarct size in vivo after ischemia/reperfusion in the rabbit heart. Circulation 2001, 103(6):877-881.
112. Zhu Y.H., Ma T.M., Wang X. Gene transfer of heat-shock protein 20 protects against ischemia/reperfusion injury in rat hearts. Acta Pharmacol Sin 2005, 26(10):1193-1200.
113. Suzuki K., Murtuza B., Sammut I.A., Latif N., Jayakumar J., Smolenski R.T., et al. Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation 2002, 106(12 Suppl 1):I270-I276.
114. Tenhunen O., Soini Y., Ilves M., Rysa J., Tuukkanen J., Serpi R., et al. p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. FASEB J 2006, 20(11):1907-1909.
115. Mazure N.M., Brahimi-Horn M.C., Pouyssegur J. Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis. Curr Pharm Des 2003, 9(7):531-541.
116. Lai Z.F., Chen Y.Z., Feng L.P., Meng X.M., Ding J.F., Wang L.Y., et al. Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury. Am J Physiol Heart Circ Physiol 2008, 295(2):H708-H716.
117. Haider H., Jiang S., Idris N.M., Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008, 103(11):1300-1308.
118. Sugano M., Tsuchida K., Hata T., Makino N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J 2004, 18(7):911-913.
119. Wang F., Trial J., Diwan A., Gao F., Birdsall H., Entman M., et al. Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol 2002, 34(10):1309-1316.
120. Gadient R.A., Patterson P.H. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 1999, 17(3):127-137.
121. Wang F., Seta Y., Baumgarten G., Engel D.J., Sivasubramanian N., Mann D.L. Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 2001, 103(9):1296-1302.
122. Kodama H., Fukuda K., Pan J., Makino S., Baba A., Hori S., et al. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1997, 81(5):656-663.
123. Berry M.F., Pirolli T.J., Jayasankar V., Morine K.J., Moise M.A., Fisher O., et al. Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure. J Thorac Cardiovasc Surg 2004, 128(6):866-875.
124. Kusano K.F., Pola R., Murayama T., Curry C., Kawamoto A., Iwakura A., et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med 2005, 11(11):1197-1204.
125. Agata J., Chao L., Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002, 40(5):653-659.
126. Zuo H., Liu Z., Liu X., Yang J., Liu T., Wen S., et al. CD151 gene delivery after myocardial infarction promotes functional neovascularization and activates FAK signaling. Mol Med 2009, 15(9-10):307-315.
127. Wang L., Yang J., Liu Z.X., Chen B., Liu J., Lan R.F., et al. Gene transfer of CD151 enhanced myocardial angiogenesis and improved cardiac function in rats with experimental myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34(2):159-163.
128. Miao W., Luo Z., Kitsis R.N., Walsh K. Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol 2000, 32(12):2397-2402.
129. Cittadini A., Monti M.G., Iaccarino G., Di Rella F., Tsichlis P.N., Di Gianni A., et al. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Ther 2006, 13(1):8-19.
130. Chinnaiyan A.M., Orth K., O'Rourke K., Duan H., Poirier G.G., Dixit V.M. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem 1996, 271(9):4573-4576.
131. Brocheriou V., Hagege A.A., Oubenaissa A., Lambert M., Mallet V.O., Duriez M., et al. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med 2000, 2(5):326-333.
132. Chatterjee S., Stewart A.S., Bish L.T., Jayasankar V., Kim E.M., Pirolli T., et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation 2002, 106(12 Suppl 1):I212-I217.
133. Chatterjee S., Bish L.T., Jayasankar V., Stewart A.S., Woo Y.J., Crow M.T., et al. Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain. J Thorac Cardiovasc Surg 2003, 125(6):1461-1469.
134. Kuwahara K., Saito Y., Kishimoto I., Miyamoto Y., Harada M., Ogawa E., et al. Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol 2000, 32(8):1385-1394.
135. Liao Z., Brar B.K., Cai Q., Stephanou A., O'Leary R.M., Pennica D., et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 2002, 53(4):902-910.
136. Ruixing Y., Jinzhen W., Dezhai Y., Jiaquan L. Cardioprotective role of cardiotrophin-1 gene transfer in a murine model of myocardial infarction. Growth Factors 2007, 25(4):286-294.
137. Takuwa Y., Okamoto Y., Yoshioka K., Takuwa N. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta 2008, 1781(9):483-488.
138. Duan H.F., Wang H., Yi J., Liu H.J., Zhang Q.W., Li L.B., et al. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007, 18(11):1119-1128.
139. Hartikainen F.M.J., Syvanne M., Stjernvall J., Hedman A., Kivela A., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107(21):2677-2683.
140. Hedman M., Muona K., Hedman A., Kivela A., Syvanne M., Eranen J., et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009, 16(5):629-634.
141. Kastrup J., Jorgensen E., Ruck A., Tagil K., Glogar D., Ruzyllo W., et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005, 45(7):982-988.
142. Gyongyosi M., Khorsand A., Zamini S., Sperker W., Strehblow C., Kastrup J., et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005, 112(9 Suppl):I157-I165.
143. Ripa R.S., Wang Y., Jorgensen E., Johnsen H.E., Hesse B., Kastrup J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006, 27(15):1785-1792.
144. Stewart D.J., Kutryk M.J., Fitchett D., Freeman M., Camack N., Su Y., et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009, 17(6):1109-1115.
145. Stewart D.J., Hilton J.D., Arnold J.M., Gregoire J., Rivard A., Archer S.L., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006, 13(21):1503-1511.
146. Losordo D.W., Vale P.R., Hendel R.C., Milliken C.E., Fortuin F.D., Cummings N., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105(17):2012-2018.
147. Reilly J.P., Grise M.A., Fortuin F.D., Vale P.R., Schaer G.L., Lopez J., et al. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol 2005, 18(1):27-31.
148. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002, 105(11):1291-1297.
149. Grines C.L., Watkins M.W., Mahmarian J.J., Iskandrian A.E., Rade J.J., Marrott P., et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003, 42(8):1339-1347.
150. Henry T.D., Grines C.L., Watkins M.W., Dib N., Barbeau G., Moreadith R., et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 11 2007, 50(11):1038-1046.
151. Su H., Joho S., Huang Y., Barcena A., Arakawa-Hoyt J., Grossman W., et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci U S A 2004, 101(46):16280-16285.
152. Tang Y. Gene therapy for myocardial ischemia using the hypoxia-inducible double plasmid system. Meth Mol Med 2005, 112:37-47.
153. Raty J.K., Lesch H.P., Wirth T., Yla-Herttuala S. Improving safety of gene therapy. Curr Drug Saf 2008, 3(1):46-53.
154. Phillips M.I., Tang Y., Schmidt-Ott K., Qian K., Kagiyama S. Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 2002, 39(2 Pt 2):651-655.
155. Fujii H., Sun Z., Li S.H., Wu J., Fazel S., Weisel R.D., et al. Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC Cardiovasc Imaging 2009, 2(7):869-879.
156. Suzuki R., Takizawa T., Negishi Y., Utoguchi N., Maruyama K. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm 2008, 354(1-2):49-55.
157. Yockman J.W., Kastenmeier A., Erickson H.M., Brumbach J.G., Whitten M.G., Albanil A., et al. Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. J Control Release 2008, 132(3):260-266.
158. Yi F., Wu H., Jia G.L., Guo W.Y., Lu A.L., Wang H.C., et al. Effect of nanoparticle with vascular endothelial growth factor gene transferred into ischemic myocardium: experiment with rabbits. Zhonghua Yi Xue Za Zhi 2006, 86(8):510-514.